<!DOCTYPE html>
<html>
<head>
	<title>Genomics England - Rare Diseases - Parathyroid cancer</title>
	<meta charset="utf-8"/>
	<script type="text/javascript" src="inc/jquery.min.js"></script>
	<link rel="stylesheet" type="text/css" href="inc/style.css" />
	<!-- <script src="../file/js/modernizr.js"></script>  -->
</head>
<body>
	<div class="container">
		<h1>Parathyroid cancer</h1>
		<div id="nav">
			<br /><br /><a href="index.html" style="margin-left:20px;">&#171; Back to homepage</a>
		</div>
		<div class="main">
			<ul class="tabs">
				<li>
					<input type="radio" checked name="tabs" id="tab1">
					<label for="tab1">Eligibility</label>
					<div id="tab-content1" class="tab-content animated fadeIn">
            
  <p class="preserve-new-lines"></p>

  <h3>Inclusion Criteria</h3>
  <p class="preserve-new-lines">- proband affected by parathyroid carcinoma (age &lt;60)  
Unaffected individuals should not be recruited in this disorder. Recruitment should favour multiplex families over single isolated cases. These singleton recruits will not contribute to the overall singleton monitoring metrics applied to GMCs.</p>

  <h3>Exclusion Criteria</h3>
  <p class="preserve-new-lines"></p>

  <h3>Prior Genetic Testing</h3>
  <p class="preserve-new-lines">- Results should have been reviewed for all genetic tests undertaken, including disease-relevant genes in exome sequencing data. The patient is not eligible if they have a molecular diagnosis for their condition. 
- Genetic testing should continue according to routine local practice for this phenotype regardless of recruitment to the project; results of these tests must be submitted via the ‘Genetic investigations’ section of the data capture tool to allow comparison of WGS with current standard testing.  

PLEASE NOTE: The sensitivity of WGS compared to current diagnostic genetic testing has not yet been established. It is therefore important that tests which are clinically indicated under local standard practice continue to be carried out.</p>

  <h3>Genes</h3>
  <p class="preserve-new-lines">Testing as below is strongly recommended PRIOR TO RECRUITMENT to allow appropriate management of families with readily detectable mutations in known disease genes:
CDC73</p>

  <h3>Closing Statement</h3>
  <p class="preserve-new-lines">These requirements will be kept under continual review during the main programme and may be subject to change.</p>


					</div>
				</li>
				<li>
					<input type="radio" name="tabs" id="tab2">
					<label for="tab2">Phenotypes</label>
					<div id="tab-content2" class="tab-content animated fadeIn">
            
  <p class="preserve-new-lines"></p>
  
    <h3><a href="http://purl.obolibrary.org/obo/HP_0006780" onclick="window.open(this.href);return false;">Parathyroid carcinoma</a></h3>
    <p class="preserve-new-lines">A malignancy of the parathyroid glands. Parathyroid carcinoma usually secretes parathyroid hormone, leading to hyperparathyroidism.</p>
  
    <h3><a href="http://purl.obolibrary.org/obo/HP_0000843" onclick="window.open(this.href);return false;">Hyperparathyroidism</a></h3>
    <p class="preserve-new-lines">Excessive production of parathyroid hormone (PTH) by the parathyroid glands.</p>
  
    <h3><a href="http://purl.obolibrary.org/obo/HP_0002897" onclick="window.open(this.href);return false;">Parathyroid adenoma</a></h3>
    <p class="preserve-new-lines">A benign tumor of the parathyroid gland that can cause hyperparathyroidism.</p>
  
    <h3><a href="http://purl.obolibrary.org/obo/HP_0003072" onclick="window.open(this.href);return false;">Hypercalcemia</a></h3>
    <p class="preserve-new-lines">An abnormally increased calcium concentration in the blood.</p>
  


					</div>
				</li>
				<li>
					<input type="radio" name="tabs" id="tab3">
					<label for="tab3">Clinical Tests</label>
					<div id="tab-content3" class="tab-content animated fadeIn">
            
  Clinical tests are not available


					</div>
				</li>
			</ul>
		</div>
	</div>
</body>
</html>
